ARCHIVES

FDA Proposes New User Fees for Generics and Biosimilar Products

This article is from The Cancer Letter archive.

Vol. 38 No. 03 | January 20, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: Last Two NCAB Choices Named; Hellman Heads ASCO, Sartorelli Named President Of AACR

May 16, 1986

Randomized Trials Discovered Roles For Newly Approved Nexavar and Sutent.

February 24, 2006

“5 A Day” Review Underway to Check Program’s Health at NCI.

March 31, 2000

Waksal Pleads Guilty To Securities Fraud

October 18, 2002

Sen. Grassley Presses Amgen on “Bundling.”

April 11, 2008

NCI-Approved Clinical Trials Listed For Month Of March

April 27, 2001